5 assets in Alveolar Rhabdomyosarcoma

Therapeutic assets addressing Alveolar Rhabdomyosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Alveolar Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Dactinomycin Alveolar Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vincristine Sulfate Alveolar Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vinorelbine Ditartrate Alveolar Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Elimusertib Alveolar Rhabdomyosarcoma	National Cancer Institute (NCI)	P1/2	CCC (48)